The increased expression of CD21 on AchR specified B cells in patients with myasthenia gravis

Journal of Neuroimmunology

Volumn 256, Issue 1-2, 2013, Pages 49-54

  Yin, Weifan ^a   Allman, Windy ^c   Ouyang, Song ^b   Li, Yi ^a   Li, Jing ^a   Christadoss, Premkumar ^c   Yang, Huan ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b First Hospital of Changsha City   (China)

^c University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Acetylcholine receptor (AchR); Autoimmunity; B cells; CD21; Myasthenia gravis (MG); Pathogenesis

Indexed keywords

CHOLINERGIC RECEPTOR; COMPLEMENT COMPONENT C3D RECEPTOR; IMMUNOGLOBULIN G;

ADOLESCENT; ADULT; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BLOOD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; IMMUNOPATHOGENESIS; MALE; MYASTHENIA GRAVIS; PATHOGENESIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; ANTIGENS, CD19; AUTOANTIBODIES; B-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; RECEPTORS, CHOLINERGIC; RECEPTORS, COMPLEMENT 3D; STATISTICS AS TOPIC;

EID: 84875369731     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.11.003     Document Type: Article

References (39)

1. Allman W., Saini S.S., Tuzun E., Christadoss P. Characterization of peripheral blood acetylcholine receptor-binding B cells in experimental myasthenia gravis. Cell. Immunol. 2011, 271:292-298.
2. Barohn R.J. Standards of measurement in myasthenia gravis. Ann. N. Y. Acad. Sci. 2003, 998:432-439.
3. Bateman K.J., Schinkel M., Little F., Liebenberg F., Vincent A., Heckmann J.M. Incidence of seropositive myasthenia gravis in Cape Town and South Africa. S. Afr. Med. J. 2007, 97:959-962.
4. Boackle S.A. Role of complement receptor 2 in the pathogenesis of systemic lupus erythematosus. Adv. Exp. Med. Biol. 2005, 560:141-147.
5. Boackle S.A., Culhane K.K., Brown J.M., Haas M., Bao L., Quigg R.J., Holers V.M. CR1/CR2 deficiency alters IgG3 autoantibody production and IgA glomerular deposition in the MRL/lpr model of SLE. Autoimmunity 2004, 37:111-123.
6. Christadoss P., Tüzün E., Li J., Saini S.S., Yang H. Classical complement pathway in experimental autoimmune myasthenia gravis pathogenesis. Ann. N. Y. Acad. Sci. 2008, 1132:210-219.
7. Del Nagro C.J., Kolla R.V., Rickert R.C., Haas M., Bao L., Quigg R.J., Holers V.M. A critical role for complement C3d and the B cell coreceptor (CD19/CD21) complex in the initiation of inflammatory arthritis. J. Immunol. 2005, 175:5379-5389.
8. Dunkelberger J.R., Song W.C. Complement and its role in innate and adaptive immune responses. Cell. Res. 2010, 20:34-50.
9. Erdei A., Isaák A., Török K., Sándor N., Kremlitzka M., Prechl J., Bajtay Z. Expression and role of CR1 and CR2 on B and T lymphocytes under physiological and autoimmune conditions. Mol. Immunol. 2009, 46:2767-2773.
10. Fischer E., Delibrias C., Kazatchkine M.D. Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes. J. Immunol. 1991, 146:865-869.
11. Grottenthaler T., Von Kempis J., Goldacker S., Illges H. Soluble CD21 in sera and synovial fluid of arthritic patients. Rheumatol. Int. 2006, 26:240-243.
12. Hoefer M.M., Illges H. Ectodomain shedding and generation of two carboxy-terminal fragments of human complement receptor 2/CD21. Mol. Immunol. 2009, 46:2630-2639.
13. Hoefer M.M., Aichem A., Knight A.M., Illges H. Modulation of murine complement receptor type 2(CR2/CD21) ectodomain shedding by its cytoplasmic domain. Mol. Immunol. 2008, 45:3434-3444.
14. Holers V.M. Complement receptors and the shaping of the natural antibody repertoire. Springer Semin. Immunopathol. 2005, 26:405-423.
15. Holers V.M., Kulik L. Complement receptor 2, natural antibodies and innate immunity: Inter-relationships in B cell selection and activation. Mol. Immunol. 2007, 44:64-72.
16. Isaák A., Prechl J., Gergely J., Erdei A. The role of CR2 in autoimmunity. Autoimmunity 2006, 39:357-366.
17. Isaák A., Gergely P., Szekeres Z., Prechl J., Poór G., Erdei A., Gergely J. Physiological up-regulation of inhibitory receptors Fc gamma RII and CR1 on memory B cells is lacking in SLE patients. Int. Immunol. 2008, 20:185-192.
18. Liu Y., Wang W., Li J. Evaluation of serum IgG subclass concentrations in myasthenia gravis. Int. J. Neurosci. 2011, 121:570-574.
19. Masilamani M., Kassahn D., Mikkat S., Glocker M.O., Illges H. B cell activation leads to shedding of complement receptor type II (CR2/CD21). Eur. J. Immunol. 2003, 33:2391-2397.
20. Masilamani M., Nowack R., Witte T., Schlesier M., Warnatz K., Glocker M.O., Peter H.H., Illges H. Reduction of soluble complement receptor 2/CD21 in systemic lupus erythomatosus and Sjogren's syndrome but not juvenile arthritis. Scand. J. Immunol. 2004, 60:625-630.
21. Masilamani M., Von Kempis J., Illges H. Decreased levels of serum soluble complement receptor-II (CR2/CD21) in patients with rheumatoid arthritis. Rheumatol (Oxford) 2004, 43:186-190.
22. McGrogan A., Sneddon S., Vries C.S. The incidence of myasthenia gravis: a systematic literature review. Neuroepidemiology 2010, 34:171-183.
23. Molnár E., Erdei A., Prechl J. Novel roles for murine complement receptors type1 and 2 I. Regulation of B cell survival and proliferation by CR1/2. Immunol. Lett. 2008, 116:156-162.
24. Patterson H.C., Kraus M., Kim Y.M., Ploegh H., Rajewsky K. The B cell receptor promotes B cell activation and proliferation through a non-ITAM tyrosine in the Igα cytoplasmic domain. Immunity 2006, 25:55-65.
25. Roozendaal R., Carroll M.C. Complement receptors CD21 and CD35 in humoral immunity. Immunol. Rev. 2007, 219:157-166.
26. Singh A., Blank M., Shoenfeld Y., Illges H. Antiphospholipid syndrome patients display reduced titers of soluble CD21 in their sera irrespective of circulating anti-beta2-glycoprotein-I autoantibodies. Rheumatol. Int. 2008, 28:661-665.
27. Singh A., Vastert S.J., Prakken B.J., Illges H. Decreased levels of sCD21 and sCD23 in blood of patients with systemic-juvenile arthritis, polyarticular-juvenile arthritis, and pauciarticular-juvenile arthritis. Rheumatol. Int. 2012, 32:1581-1587.
28. Souroujon M.C., Brenner T., Fuchs S. Development of novel therapies for MG: studies in animal models. Autoimmunity 2010, 43:446-460.
29. Toepfner N., Cepok S., Grummel V., Hemmer B. The role of the Epstein-Barr virus receptor CD21 in multiple sclerosis. J. Neuroimmunol. 2012, 242:47-51.
30. Turner C. A review of myasthenia gravis: pathogenesis, clinical features and treatment. Curr. Anaesth. Crit. Care 2007, 18:15-23.
31. Tüzün E., Scott B.G., Goluszko E., Higgs E., Christadoss P. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. J. Immunol. 2003, 171:3847-3854.
32. Tüzün E., Scott B.G., Yang H., Wu B., Goluszko E., Guigneaux M., Higgs S., Christadoss P. Circulating immune complexes augment severity of antibody mediated myasthenia gravis in hypogammaglobulinemic RIIIS/J mice. J. Immunol. 2004, 172:5743-5752.
33. Tüzün E., Li J., Saini S.S., Yang H., Christadoss P. Targeting classical complement pathway to treat complement mediated autoimmune diseases. Adv. Exp. Med. Biol. 2008, 632:265-272.
34. Tüzün E., Huda R., Christadoss P. Complement and cytokine based therapeutic strategies in myasthenia gravis. J. Autoimmun. 2010, 37:136-143.
35. Twohig J.P., Pappworth I.Y., Sivasankar B., Kulik L., Bull M., Holers V.M., Wang E.C., Marchbank K.J. Defective B cell ontogeny and humoral immune response in mice prematurely expressing human complement receptor 2 (CR2, CD21) is similar to that seen in aging wild type mice. Mol. Immunol. 2009, 46:2002-2013.
36. Wagner E., Frank M.M. Therapeutic potential of complement modulation. Nat. Rev. Drug. Discov. 2010, 9:43-56.
37. Wehr C., Eibei H., Masilamani M., IIIges H., Schlesier M., Peter H.H., Warnatz K. A new CD21 low B cell population in the peripheral blood of patients with SLE. Clin. Immunol. 2004, 113:161-171.
38. Wu B., Goluszko E., Christadoss P. Experimental autoimmune myasthenia gravis in the mouse. Curr. Protoc. Immunol. 2001, 15:8. (Chaper 15. Unit).
39. Zhang R., Wang Q.J., Xu J.M., Jiang L., Shou W.Z., Yin Y. Expression of CD21 in peripheral blood B lymphocytes of neonates. Zhongguo Dang Dai Er Ke Za Zhi 2007, 9:546-548. (article in Chinese).